Lunit, a leading provider of AI-powered cancer diagnostics and therapeutics, has announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to advance AI applications in cancer research. The partnership focuses on exploring the tumor microenvironment and immune phenotyping, leveraging Lunit’s AI-driven biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC, to analyze whole-slide images from NCI’s clinical trials. As part of the agreement, Lunit’s tools will be made available to investigators at the NCI Center for Cancer Research (CCR), integrating AI-powered image analysis into cancer research practices.
The collaboration aims to generate data-driven insights that enhance personalized cancer treatment, optimize immunotherapy strategies, and improve patient outcomes. Lunit and NCI will jointly prepare publications, presentations, and reports to accelerate discoveries in oncology. By applying AI solutions across NCI’s extensive research portfolio, the partnership seeks to drive advancements in precision medicine and targeted cancer therapies.
"This collaboration with NCI underscores the potential of Lunit’s AI-driven technologies to transform cancer research," said Brandon Suh, CEO of Lunit. "By combining our expertise with NCI’s unparalleled research capabilities, we aim to uncover meaningful insights that can revolutionize cancer treatment and improve patient care worldwide."
Click here to read the original news story.